Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Completed 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Sarcoma 1Genitourinary 1

Conditions

Carcinoma, Non-Small-Cell Lung 3Stomach Neoplasms 2Carcinoma, Renal Cell 2Triple Negative Breast Neoplasms 1Squamous Cell Carcinoma of Head and Neck 1Solitary Fibrous Tumor, Pleural 1Seminoma 1Sarcoma, Clear Cell 1Sarcoma, Alveolar Soft Part 1Renal Insufficiency 1Prostatic Neoplasms 1Paraproteinemias 1Pancreatic Neoplasms 1Osteolysis 1Multiple Myeloma 1Mesothelioma, Malignant 1Hypercalcemia 1Hematologic Neoplasms 1Fractures, Spontaneous 1Colorectal Cancer Metastatic 1Carcinoma, Small Cell 1Carcinoma 1Breast Neoplasms 1Bone Diseases, Metabolic 1Anemia 1Amyloidosis 1

Interventions

tebentafusp 1dostarlimab 1cobimetinib 1cabozantinib 1atezolizumab 1Vemurafenib 1Specimen Handling 1Radiation Dose Hypofractionation 1Diathermy 1Crizotinib 1Biopsy 1ARQ 197 1AMG 337 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Phase 2 × Sarcoma, Clear Cell × ARQ 197 × Clear all
NCT00557609 2013-02-08

Phase 2 Study in Patients With MiT Tumors

ArQule, Inc., a subsidiary of Merck Sharp & Dohme LLC, a subsidiary of Merck & Co., Inc. (Rahway, NJ USA)

Phase 2 Completed
47 enrolled
GenitourinarySarcoma

Carcinoma, Renal Cell, Sarcoma, Clear Cell, Sarcoma, Alveolar Soft Part

Data powered by HemOnc (CC BY 4.0) Colophon âš¡